Floatz logo

Tucatinib

HER2 Positive Breast Carcinoma

MedSIRSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

175 Active assets in the HER2 Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB
Vinorelbine Ditartrate
Fudan University
Phase 3BB
Docetaxel
Ohio State University Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
invasive breast carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
metastatic neoplasmActive
B
Indicative · Phase 2
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →